Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0524 in Chronic Asthma
NCT00783601Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2004
- Primary completion
- May 2005
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of laropiprant in asthma (2 arms), sponsored by Merck & Co. Primary endpoint: Forced Expiratory Volume in 1 second. Started Oct 2004; status: completed.
02
Drugs
laropiprant
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00783601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00783601.